Welcome to our dedicated page for Bioceres Crop Solutions SEC filings (Ticker: BIOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioceres Crop Solutions Corp. filings document a foreign private issuer reporting through Form 6-K as a Form 20-F filer, with interim results, press releases and XBRL-tagged financial data prepared under IFRS. The disclosures cover revenue and margin trends by crop protection, seed and integrated products, and crop nutrition, along with currency risk, property and equipment, debt securities, bank borrowings, subsidiaries, joint ventures and associates.
The filing record also includes annual general meeting proxy materials, Nasdaq minimum bid-price correspondence, and material-event reports involving convertible and non-convertible note purchase agreements, acceleration notices, collateral matters and Pro Farm-related proceedings. Certain Form 6-K reports are incorporated by reference into Form F-3 and Form S-8 registration statements, linking current reports to the company's securities registration disclosures.
Bioceres Crop Solutions Corp. director Duraiswami Narain reported initial holdings of stock options representing the right to buy 150,000 Ordinary Shares. The options have an exercise price of $1.50 per share, become exercisable on June 30, 2028, and expire on June 30, 2033. All holdings in this filing are reported as held directly.
Bioceres Crop Solutions reported fiscal third quarter 2026 results showing weaker sales and profitability as it refocuses operations after exiting the Pro Farm business. Continuing-operations revenue was $39.4 million, down 23% year over year, with Crop Protection at $24.6 million, Seed and Integrated Products at $3.2 million, and Crop Nutrition at $11.6 million.
Gross profit fell to $12.7 million, and gross margin slipped from 35% to 32%, hurt by product mix and a non-recurring inoculant obsolescence adjustment. The company posted a net loss of $10.0 million versus a $2.3 million profit a year earlier, while Adjusted EBITDA moved from $9.1 million to $(0.6) million.
Bioceres reduced SG&A expenses by 16% to $16.1 million and continued cost and working-capital initiatives, but higher financial costs pushed total financial result to $(9.7) million. As of March 31, 2026, total debt was $228.8 million, net financial debt was $214.0 million, and cash and short-term investments were $14.8 million. Equity attributable to owners fell to $67.7 million, reflecting the earlier Pro Farm foreclosure and related ~$194 million derecognition of net assets and non-cash loss; the associated note acceleration remains under legal dispute.
Bioceres Crop Solutions Corp. CFO Ezequiel Simmermacher has filed an amended Form 3, which is the initial insider ownership report required for company officers. The amendment does not list any new stock transactions or derivative positions and instead updates previously reported ownership details.
Bioceres Crop Solutions Corp. director Yogesh Mago filed an initial ownership report on Form 3. The filing shows direct holdings of 55,399 Ordinary Shares of the company. This is a baseline disclosure of his equity position and does not reflect any recent purchase or sale activity.
Bioceres Crop Solutions Corp. CEO Federico Trucco filed an initial ownership report showing his existing stake in the company. He directly holds 356,000 Ordinary Shares. He also holds stock options over 1,300,000 Ordinary Shares, including 1,000,000 options at an exercise price of $10.47 per share expiring in 2030 and 300,000 options at $4.55 per share expiring in 2029. This filing records current holdings and does not report any new purchases or sales.
Agriculture Investment Group Corp. and its subsidiary Granosur Holding Limited have reduced their stake in Bioceres Crop Solutions Corp. They now beneficially own 5,072,705 ordinary shares, representing 7.95% of the company’s outstanding ordinary shares, based on 63,815,891 shares outstanding as of December 31, 2025.
The decrease results from Granosur’s sale of an aggregate 704,102 shares in a series of open market transactions between March 23, 2026 and April 24, 2026, at prices ranging from $0.37 to $0.63 per share. The reporting persons state they currently have no specific plans for corporate actions regarding Bioceres but may change their intentions over time.
Bioceres Crop Solutions Corp. General Counsel Roque Jose Augusto has filed an initial Form 3 showing his equity holdings in the company. He directly owns 667 Ordinary Shares and holds stock options covering 40,000 Ordinary Shares at an exercise price of $10.47 per share. These options become exercisable on August 21, 2025 and expire on August 21, 2028. The filing reports existing positions and does not show any recent share purchases or sales.
Bioceres Crop Solutions Corp. CFO Ezequiel Simmermacher has filed an initial Form 3, which is the required statement of beneficial ownership for company insiders. The filing reports no transactions, meaning there are currently no disclosed purchases, sales, or derivative exercises associated with this insider in this report.
Agriculture Investment Group Corp. and Granosur Holding Limited filed an amended Schedule 13D reporting a reduced stake in Bioceres Crop Solutions Corp. They now beneficially own 5,776,807 Ordinary Shares, representing 9.05% of the company, based on 63,815,891 shares outstanding as of December 31, 2025.
The change reflects share sales in Bioceres. In connection with the transaction, AIGC sold 1,077,973 shares and Granosur sold 23,193 shares. Item 5 details open-market sales between March 13 and March 20, 2026 at average prices between $0.36 and $0.53 per share, with each day’s aggregate gross proceeds disclosed.
Bioceres Crop Solutions Corp. reported that it received a Nasdaq bid-price deficiency notice after its ordinary shares closed below $1.00 for 30 consecutive business days, breaching Nasdaq Listing Rule 5450(a)(1). The notice does not immediately affect the Nasdaq Global Select Market listing, and the BIOX shares continue to trade.
Bioceres has 180 calendar days, until September 14, 2026, to regain compliance by having a closing bid price at or above $1.00 for at least ten consecutive business days. If it fails to do so, the company may seek an additional 180-day period but could ultimately face delisting if it cannot meet Nasdaq’s requirements. Management states it is committed to regaining compliance and will monitor the share price and consider available options.